Sun Pharma gets U.S. approval for Paraplatin injection
Thursday, 25 September 2008, 00:53 IST
Printer Print Email Email
New Delhi: Sun Pharmaceutical Industries Ltd Tuesday said it has got the U.S. Food and Drug Administration (USFDA) approval for the abbreviated new drug application (ANDA) to market generic Paraplatin, a carboplatin injection. These generic versions of carboplatin 10 mg/ml injections, packed in 5 ml, 15 ml and 45 ml single use vials, are bio-equivalent to Paraplatin injections distributed by Bristol Myers Squibb Oncology/Virology, a patient assistance program provided by Bristol Myers Squibb Co. The injections are mainly utilised during initial and secondary therapy in patients with advanced ovarian carcinoma. These strengths of Paraplatin injections have annual sales of approximately $45 million in the U.S.
Source: IANS
siliconindia